Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1984 Jul;74(1):212–223. doi: 10.1172/JCI111404

Pharmacology and inotropic potential of forskolin in the human heart.

M R Bristow, R Ginsburg, A Strosberg, W Montgomery, W Minobe
PMCID: PMC425203  PMID: 6330174

Abstract

We evaluated the effects of the diterpene compound forskolin in human myocardial adenylate cyclase preparations, isolated trabeculae and papillary muscles derived from failing human hearts, and acutely instrumented dogs. Forskolin was a potent, powerful activator of human myocardial adenylate cyclase and produced maximal effects that were 4.82 (normally functioning left ventricle) and 6.13 (failing left ventricle) fold greater than isoproterenol. In contrast to isoproterenol, forskolin retained full activity in membrane preparations derived from failing hearts. In cyclase preparations, forskolin demonstrated unique substrate and Mg2+ kinetic properties that could be distinguished from hormone receptor-coupled agonists or fluoride ion. The adenylate cyclase stimulatory effect of forskolin was synergistic with isoproterenol, apparently due to the location of forskolin activation being beyond the level of hormone receptor-agonist in the receptor-cyclase complex. Forskolin was a potent positive inotrope in failing human myocardium, producing a stimulation of contraction that was similar to isoproterenol. Finally, in open chest dogs forskolin was a positive inotropic agent that reduced preload and afterload. We conclude that forskolin belongs to a class of agents that may have therapeutic potential in the treatment of congestive heart failure.

Full text

PDF
212

Images in this article

219Image
on p.219

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Applefeld M. M., Newman K. A., Grove W. R., Sutton F. J., Roffman D. S., Reed W. P., Linberg S. E. Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure. Am J Cardiol. 1983 Feb;51(3):455–458. doi: 10.1016/s0002-9149(83)80079-4. [DOI] [PubMed] [Google Scholar]
  2. Bobik A., Campbell J. H., Carson V., Campbell G. R. Mechanism of isoprenaline-induced refractoriness of the beta-adrenoceptor--adenylate cyclase system in chick embryo cardiac cells. J Cardiovasc Pharmacol. 1981 May-Jun;3(3):541–553. doi: 10.1097/00005344-198105000-00013. [DOI] [PubMed] [Google Scholar]
  3. Bristow M. R., Cubicciotti R., Ginsburg R., Stinson E. B., Johnson C. Histamine-mediated adenylate cyclase stimulation in human myocardium. Mol Pharmacol. 1982 May;21(3):671–679. [PubMed] [Google Scholar]
  4. Bristow M. R., Ginsburg R., Minobe W., Cubicciotti R. S., Sageman W. S., Lurie K., Billingham M. E., Harrison D. C., Stinson E. B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22;307(4):205–211. doi: 10.1056/NEJM198207223070401. [DOI] [PubMed] [Google Scholar]
  5. Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
  6. Darfler F. J., Mahan L. C., Koachman A. M., Insel P. A. Stimulation of forskolin of intact S49 lymphoma cells involves the nucleotide regulatory protein of adenylate cyclase. J Biol Chem. 1982 Oct 25;257(20):11901–11907. [PubMed] [Google Scholar]
  7. DeLean A., Munson P. J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978 Aug;235(2):E97–102. doi: 10.1152/ajpendo.1978.235.2.E97. [DOI] [PubMed] [Google Scholar]
  8. Drummond G. I., Severson D. L. Cyclic nucleotides and cardiac function. Circ Res. 1979 Feb;44(2):145–153. doi: 10.1161/01.res.44.2.145. [DOI] [PubMed] [Google Scholar]
  9. Engel G., Hoyer D., Berthold R., Wagner H. (+/-)[125Iodo] cyanopindolol, a new ligand for beta-adrenoceptors: identification and quantitation of subclasses of beta-adrenoceptors in guinea pig. Naunyn Schmiedebergs Arch Pharmacol. 1981;317(4):277–285. doi: 10.1007/BF00501307. [DOI] [PubMed] [Google Scholar]
  10. Epstein S. E., Skelton C. L., Levey G. S., Entman M. Adenyl cyclase and myocardial contractility. Ann Intern Med. 1970 Apr;72(4):561–578. doi: 10.7326/0003-4819-72-4-561. [DOI] [PubMed] [Google Scholar]
  11. Erbel R., Meyer J., Lambertz H., Schweizer P., Voelker W., Krebs W., Braun G., Effert S. Hemodynamic effects of prenalterol in patients with ischemic heart disease and congestive cardiomyopathy. Circulation. 1982 Aug;66(2):361–369. doi: 10.1161/01.cir.66.2.361. [DOI] [PubMed] [Google Scholar]
  12. Ginsburg R., Bristow M. R., Billingham M. E., Stinson E. B., Schroeder J. S., Harrison D. C. Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J. 1983 Sep;106(3):535–540. doi: 10.1016/0002-8703(83)90698-1. [DOI] [PubMed] [Google Scholar]
  13. Ginsburg R., Esserman L. J., Bristow M. R. Myocardial performance and extracellular ionized calcium in a severely failing human heart. Ann Intern Med. 1983 May;98(5 Pt 1):603–606. doi: 10.7326/0003-4819-98-5-603. [DOI] [PubMed] [Google Scholar]
  14. Goldberg L. I. Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med. 1974 Oct 3;291(14):707–710. doi: 10.1056/NEJM197410032911405. [DOI] [PubMed] [Google Scholar]
  15. Hoyer D., Engel G., Berthold R. Binding characteristics of (+)-, (+/-)- and (-)-[125iodo] cyanopindolol to guinea-pig left ventricle membranes. Naunyn Schmiedebergs Arch Pharmacol. 1982 Mar;318(4):319–329. doi: 10.1007/BF00501172. [DOI] [PubMed] [Google Scholar]
  16. Hudson T. H., Fain J. N. Forskolin-activated adenylate cyclase. Inhibition by guanyl-5'-yl imidodiphosphate. J Biol Chem. 1983 Aug 25;258(16):9755–9761. [PubMed] [Google Scholar]
  17. Johnson G. L., Kaslow H. R., Farfel Z., Bourne H. R. Genetic analysis of hormone-sensitive adenylate cyclase. Adv Cyclic Nucleotide Res. 1980;13:1–37. [PubMed] [Google Scholar]
  18. Kenakin T. P., Ferris R. M. Effects of in vivo beta-adrenoceptor down-regulation on cardiac responses to prenalterol and pirbuterol. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):90–97. doi: 10.1097/00005344-198301000-00014. [DOI] [PubMed] [Google Scholar]
  19. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  20. Leier C. V., Unverferth D. V. Drugs five years later. Dobutamine. Ann Intern Med. 1983 Oct;99(4):490–496. doi: 10.7326/0003-4819-99-4-490. [DOI] [PubMed] [Google Scholar]
  21. Lindner E., Dohadwalla A. N., Bhattacharya B. K. Positive inotropic and blood pressure lowering activity of a diterpene derivative isolated from Coleus forskohli: Forskolin. Arzneimittelforschung. 1978;28(2):284–289. [PubMed] [Google Scholar]
  22. Marsh J. D., Barry W. H., Neer E. J., Alexander R. W., Smith T. W. Evidence for uncoupling of the beta receptor-adenylate cyclase complex. Circ Res. 1980 Oct;47(4):493–501. doi: 10.1161/01.res.47.4.493. [DOI] [PubMed] [Google Scholar]
  23. Metzger H., Lindner E. The positive inotropic-acting forskolin, a potent adenylate cyclase activator. Arzneimittelforschung. 1981;31(8):1248–1250. [PubMed] [Google Scholar]
  24. Ross E. M., Maguire M. E., Sturgill T. W., Biltonen R. L., Gilman A. G. Relationship between the beta-adrenergic receptor and adenylate cyclase. J Biol Chem. 1977 Aug 25;252(16):5761–5775. [PubMed] [Google Scholar]
  25. Seamon K. B., Padgett W., Daly J. W. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3363–3367. doi: 10.1073/pnas.78.6.3363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Seamon K., Daly J. W. Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem. 1981 Oct 10;256(19):9799–9801. [PubMed] [Google Scholar]
  27. Su Y. F., Harden T. K., Perkins J. P. Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process. J Biol Chem. 1980 Aug 10;255(15):7410–7419. [PubMed] [Google Scholar]
  28. Tse J., Powell J. R., Baste C. A., Priest R. E., Kuo J. F. Isoproterenol-induced cardiac hypertrophy: modifications in characteristics of beta-adrenergic receptor, adenylate cyclase, and ventricular contraction. Endocrinology. 1979 Jul;105(1):246–255. doi: 10.1210/endo-105-1-246. [DOI] [PubMed] [Google Scholar]
  29. Waelbroeck M., Taton G., Delhaye M., Chatelain P., Camus J. C., Pochet R., Leclerc J. L., De Smet J. M., Robberecht P., Christophe J. The human heart beta-adrenergic receptors. II. Coupling of beta 2-adrenergic receptors with the adenylate cyclase system. Mol Pharmacol. 1983 Sep;24(2):174–182. [PubMed] [Google Scholar]
  30. Weber K. T., Andrews V., Janicki J. S., Likoff M., Reichek N. Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. Circulation. 1982 Dec;66(6):1262–1267. doi: 10.1161/01.cir.66.6.1262. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES